Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.96 USD | +2.08% | -3.45% | +36.11% |
Apr. 23 | Silo Pharma, Inc. Announces Positive Results for Intranasal PTSD Treatment | CI |
Apr. 10 | Silo Pharma Says It Exercised Option to License Alzheimer's Therapeutic From Columbia University | MT |
Financials (USD)
Sales 2024 * | 72K | Sales 2025 * | 72K | Capitalization | 5.46M |
---|---|---|---|---|---|
Net income 2024 * | -4M | Net income 2025 * | -8M | EV / Sales 2024 * | 75.8 x |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 75.8 x |
P/E ratio 2024 * |
-3.5
x | P/E ratio 2025 * |
-2.8
x | Employees | 3 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 83.83% |
1 day | +2.08% | ||
1 week | -3.45% | ||
Current month | +6.66% | ||
1 month | +5.95% | ||
3 months | +26.45% | ||
6 months | +10.73% | ||
Current year | +36.11% |
Managers | Title | Age | Since |
---|---|---|---|
Eric Weisblum
CEO | Chief Executive Officer | 54 | 10-07-12 |
Daniel Ryweck
DFI | Director of Finance/CFO | 59 | 22-09-26 |
James Kuo
CTO | Chief Tech/Sci/R&D Officer | 58 | 22-08-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Eric Weisblum
CEO | Chief Executive Officer | 54 | 10-07-12 |
Wayne Linsley
BRD | Director/Board Member | 67 | 20-01-15 |
Kevin Muñoz
BRD | Director/Board Member | 46 | 20-09-30 |
Date | Price | Change | Volume |
---|---|---|---|
24-05-28 | 1.96 | +2.08% | 58,556 |
24-05-24 | 1.92 | -3.52% | 56,556 |
24-05-23 | 1.99 | -13.48% | 239,980 |
24-05-22 | 2.3 | +5.50% | 179,798 |
24-05-21 | 2.18 | +7.39% | 809,986 |
Delayed Quote Nasdaq, May 28, 2024 at 04:30 pm EDT
More quotesEPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+36.11% | 5.46M | |
-1.64% | 90.28B | |
-1.97% | 39.5B | |
-15.47% | 31.71B | |
+61.28% | 26.41B | |
-22.81% | 14.34B | |
-8.82% | 12.89B | |
-11.77% | 11.8B | |
-45.97% | 10.95B | |
+3.30% | 8.85B |
- Stock Market
- Equities
- SILO Stock